Posted by Michael Wonder on 02 Feb 2021
Novo Nordisk receives positive opinion from the European regulatory authorities for once-weekly Sogroya (somapacitan) for the treatment of adult growth hormone deficiency
29 January 2021 - Novo Nordisk announced today that the CHMP, under the EMA, adopted a positive opinion for the use of once-weekly Sogroya (somapacitan), recommending marketing authorisation for the treatment of adults with growth hormone deficiency.
This recommendation is based on the results from REAL 1, a clinical trial programme investigating the efficacy and safety of Sogroya (somapacitan) in adults with growth hormone deficiency.
